Description

Montelukast-d6 (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].-4°C (Powder, sealed storage, away from moisture)-Applications–Formula-C35H29D6ClNNaO3S-Citation–References-[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Pu S, et, al. Montelukast Prevents Mice Against Acetaminophen-Induced Liver Injury. Front Pharmacol. 2019 Sep 18; 10:1070.;William RHJ, et, al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002 Jan 1; 165(1): 108-16.-CASNumber-2673270-26-1-MolecularWeight-614.20-Compound Purity-96.0-SMILES-[2H]C([2H])([2H])C(C([2H])([2H])[2H])(O)C(C=CC=C1)=C1CC[C@H](C2=CC(/C=C/C3=NC4=C(C=CC(Cl)=C4)C=C3)=CC=C2)SCC5(CC5)CC(O[Na])=O-Research_Area-Inflammation/Immunology-Solubility-10 mM in DMSO-Target-Leukotriene Receptor-Isoform–Pathway-GPCR/G Protein-MCE Product type-Isotope-Labeled Compounds